1. Home
  2. IDE vs HUMA Comparison

IDE vs HUMA Comparison

Compare IDE & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

IDE

Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

HOLD

Current Price

$13.51

Market Cap

210.5M

Sector

Finance

ML Signal

HOLD

Logo Humacyte Inc.

HUMA

Humacyte Inc.

HOLD

Current Price

$0.66

Market Cap

191.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDE
HUMA
Founded
2010
2004
Country
United States
United States
Employees
N/A
184
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
210.5M
191.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IDE
HUMA
Price
$13.51
$0.66
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$6.19
AVG Volume (30 Days)
35.2K
18.0M
Earning Date
01-01-0001
05-15-2026
Dividend Yield
8.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$444.16
Revenue Next Year
N/A
$248.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.36
$0.55
52 Week High
$14.30
$2.84

Technical Indicators

Market Signals
Indicator
IDE
HUMA
Relative Strength Index (RSI) 44.70 36.22
Support Level $13.33 $0.65
Resistance Level $13.96 $1.26
Average True Range (ATR) 0.20 0.07
MACD -0.01 0.00
Stochastic Oscillator 31.25 10.91

Price Performance

Historical Comparison
IDE
HUMA

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

About HUMA Humacyte Inc.

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: